Sodium polystyrene sulfonate (SPS or Kayexalate), a treatment for hyperkalemia, was approved by the FDA in 1958, which was before the time the FDA required safety and efficacy reporting for drug approval. In 2009, the FDA issued a warning about the association of kayexalate-sorbitol use (which is the common preparation used in the US) due to reports of colonic necrosis. This study reviewed efficacy data for kayexalate-sorbitol and found no convincing evidence that it significantly lowers serum potassium. Given the lack of efficacy data, and recent reports of harm, we should question our use of this drug in hospitalized patients (abstract)
|
June 11, 2010 |
0 
About the Author: Danielle Scheurer
Dr. Scheurer is a clinical hospitalist and the Medical Director of Quality and Safety at the Medical University of South Carolina in Charleston, South Carolina, and is Assistant Professor of Medicine. She is a graduate of the University of Tennessee College of Medicine, completed her residency at Duke University, and completed her Masters in Clinical Research at the Medical University of South Carolina. She also serves as the Web Editor and Physician Advisor for the Society of Hospital Medicine.
Categories
Related Posts
| June 29, 2013 | 0
0This large systematic review found rectal NSAIDs significantly reduced the risk of post-ERCP pancreatitis compared to pancreatic duct stents (abstract).
| June 22, 2013 | 0
0This large population-based cohort found the most common causes of drug induced liver injury to be augmentin and diclofenac, followed by herbal and nutritional supplements (abstract).
| May 25, 2013 | 0
0This large trial of patients with a relative contraindication for enteral feeds were randomized to early TPN or usual care. There were no differences in the groups in 60 day mortality or LOS, but those on TPN did have a shorter time ventilated and less muscle/fat loss. It is unclear based on this trial if […]
Leave A Comment